Proton pump inhibitors (PPIs) are a class of very effective and generally safe medicines used to treat heartburn, gastroesophageal reflux disease (GERD), and gastric ulcers.But not everyone who ...

Additionally, the authors designed and synthesized a biotinylated cyclic peptide probe, BIOTIN-DC646, to validate its role as a PPI inhibitor using co-immunoprecipitation experiments. FXR is ...

Although 5 proton-pump inhibitors (PPIs) are available in the U.S., no 5-way studies have compared their efficacy in relieving symptoms of gastroesophageal reflux. In this randomized, open-label ...

More information: Shun Nakamura et al, Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes, Proceedings of the National Academy of Sciences (2025).

Additionally, the authors designed and synthesized a biotinylated cyclic peptide probe, BIOTIN-DC646, to validate its role as a PPI inhibitor using co-immunoprecipitation experiments. FXR is ...

Figure 1: Examples of small-molecule inhibitors of PPI targets. The ideal small-molecule drug target has a structure that falls into a class known to be 'druggable' and has well-understood biology ...

The study objective was to evaluate the association of proton pump inhibitors (PPIs) and community-acquired pneumonia (CAP). The design was a meta-analysis of nine case–controlled and cohort ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking ...

has developed COVID-19 eliminative Short Peptide Inhibiting ACE2 binding (CeSPIACE), a mutation-tolerant spike protein inhibitor that remains effective against SARS-CoV-2 variants, including ...